Previous 10 | Next 10 |
CorMedix (CRMD) announces the appointment of Thomas Nusbickel to the newly created position of Chief Commercial Officer.Nusbickel most recently served as Vice President of Market Access and Government Affairs at Coherus Biosciences. For further details see: CorMedix names...
BERKELEY HEIGHTS, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Thoma...
BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its ...
BERKELEY HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix manageme...
The following slide deck was published by CorMedix Inc. in conjunction with this event. For further details see: CorMedix (CRMD) Investor Presentation - Slideshow
Gainers: Cinedigm (CIDM) +20%.Grupo Televisa (TV) +20%.GameStop (GME) +18%.Nurix Therapeutics (NRIX) +18%.Centennial Resource Development (CDEV) +17%.Regulus Therapeutics (RGLS) +16%.NexImmune (NEXI) +16%.UP Fintech (TIGR) +16%.Kymera Therapeutics (KYMR) +15%.Transocean (RIG) +...
Gainers: Galectin Therapeutics (GALT) +17%, NexImmune (NEXI) +16%, Kymera Therapeutics (KYMR) +15%, Nurix Therapeutics (NRIX) +15%, DBV Technologies (DBVT) +13%.Losers: LifeMD (LFMD) -24%, CorMedix (CRMD) -11%, Cleveland BioLabs (CBLI) -9...
CorMedix (CRMD) has met with the FDA to discuss solutions to the deficiencies identified in the Complete Response Letter (“CRL”) to its marketing application for DefenCath™ (taurolidine/heparin catheter lock solution).The discussions have also involved the third-party man...
BERKELEY HEIGHTS, N.J., April 14, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has met with t...
Today we look at CorMedix, whose shares have had a wild ride thanks primarily to the CRL it received from the FDA around its primary drug candidate. The CRL is likely to be resolved, but does that mean investors should buy the dip in this stock? A full analysis on CorMedix and our...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...